
ID: uzexd9h1,
Text: drug repurposing prediction for covid using probabilistic networks and crowdsourced curation severe acute respiratory syndrome coronavirus two sars cov the virus responsible for the coronavirus disease covid pandemic represents an unprecedented global health challenge consequently a large amount of research into the disease pathogenesis and potential treatments has been carried out in a short time frame however developing novel drugs is a costly and lengthy process and is unlikely to deliver a timely treatment for the pandemic drug repurposing by contrast provides an attractive alternative as existing drugs have already undergone many of the regulatory requirements in this work we used a combination of network algorithms and human curation to search integrated knowledge graphs identifying drug repurposing opportunities for covid we demonstrate the value of this approach reporting on eight potential repurposing opportunities identified and discuss how this approach could be incorporated into future studies

ID: r4snyxr9,
Text: repurposing host based therapeutics to control coronavirus and influenza virus the development of highly effective antiviral agents has been a major objective in virology and pharmaceutics drug repositioning has emerged as a cost effective and time efficient alternative approach to traditional drug discovery and development this new shift focuses on the repurposing of clinically approved drugs and promising preclinical drug candidates for the therapeutic development of host based antiviral agents to control diseases caused by coronavirus and influenza virus host based antiviral agents target host cellular machineries essential for viral infections or innate immune responses to interfere with viral pathogenesis this review discusses current knowledge prospective applications and challenges in the repurposing of clinically approved and preclinically studied drugs for newly indicated antiviral therapeutics

ID: l76lspvx,
Text: coronavirus puts drug repurposing on the fast track

ID: 7r6j9dgo,
Text: coronavirus puts drug repurposing on the fast track

ID: hcj8fylw,
Text: perspectives for repurposing drugs for the coronavirus disease the newly emerged novel coronavirus cov named as severe acute respiratory syndrome cov sars cov like sars cov now sars cov and middle east respiratory syndrome cov mers cov has been associated with high infection rates with over deaths in the absence of approved marketed drugs against coronaviruses the treatment and management of this novel cov disease covid worldwide is a challenge drug repurposing that has emerged as an effective drug discovery approach from earlier approved drugs could reduce the time and cost compared to de novo drug discovery direct virus targeted antiviral agents target specific nucleic acid or proteins of the virus while host based antivirals target either the host innate immune responses or the cellular machineries that are crucial for viral infection both the approaches necessarily interfere with viral pathogenesis here we summarize the present status of both virus based and host based drug repurposing perspectives for coronaviruses in general and the sars cov in particular

ID: 2rlld533,
Text: a brief overview of current drug repurposing approaches for covid management this brief overview is intended to shed light on the current drug repositioning also called drug repurposing in the therapeutics of the novel coronavirus disease which emerged in covid in this sense the repositioning drugs for new indications can offer a better risk versus reward trade off when compared to other drug development strategies given that it makes use of drugs whose safety profile are already understood nonetheless this approach allows healthcare professionals to promptly tackle the disease by investigating readily available drugs against it

ID: q6bpic9m,
Text: current status of covid therapies and drug repositioning applications the rapid and global spread of a new human coronavirus sars cov has produced an immediate urgency to discover promising targets for the treatment of covid drug repositioning is an attractive approach that can facilitate the drug discovery process by repurposing existing pharmaceuticals to treat illnesses other than their primary indications here we review current information concerning the global health issue of covid including promising approved drugs and ongoing clinical trials for prospective treatment options in addition we describe computational approaches to be used in drug repurposing and highlight examples of in silico studies of drug development efforts against sars cov

ID: qmlmiqtv,
Text: combating devastating covid by drug repurposing despite advances in drug discovery viral infections remain a major challenge for scientists across the globe the recent pandemic of covid coronavirus disease caused by a viral infection with sars cov severe acute respiratory syndrome coronavirus has created a disastrous situation all over the world as no drugs are available to treat this life threatening disease and the mortality rate due to covid is high there is an utmost need to attempt to treat the infection using drug repurposing some countries are against the use of these drugs because of adverse effects associated with drug repurposing and lack of statistically significant clinical data but they have been found to be effective in some countries to treat covid patients off label investigational this article emphasises possible drug candidates in the treatment of covid most of these drugs were found to be effective in in vitro studies there is a need to re assess in vitro data and to carry out randomised clinical trials further investigations of these drugs are recommended on a priority basis

ID: 1t4ykc01,
Text: current status of covid therapies and drug repositioning applications summary the rapid and global spread of a new human coronavirus sars cov has produced an immediate urgency to discover promising targets for treatment of covid drug repositioning is an attractive approach that can facilitate the drug discovery process by repurposing existing pharmaceuticals to treat illnesses other than their primary indications here we review current information concerning the global health issue of covid including promising approved drugs and ongoing clinical trials for prospective treatment options in addition we describe computational approaches to be used in drug repurposing and highlight examples of in silico studies of drug development efforts against sars cov

ID: s953j62y,
Text: computational studies of drug repurposing and synergism of lopinavir oseltamivir and ritonavir binding with sars cov protease against covid a novel coronavirus sars cov has caused a major outbreak in humans all over the world and it is the latest pandemic in the series of other infectious diseases the concept of drug repurposing has been used successfully for many years for known diseases considering the emergency and urgency drug repurposing concept is being explored for coronavirus disease covid as well recently the combination of three known drugs lopinavir oseltamivir and ritonavir has been proposed to control the virulence to a great extent in covid affected patients within hours hence we tried to understand the effect of synergism of these drugs against the sars cov protease using sequential docking studies as a result combination of three drugs showed a better binding energy than that of individual drugs further the complex was subjected to molecular dynamics simulations to get insights into the stability of the complex considering the simultaneous interactions between three drugs and the protein the protein complexed with three drugs remained stable during the simulations hence these drugs can be explored further for drug repurposing against the successful inhibition of covid

ID: b4mdiont,
Text: network based drug repurposing for human coronavirus human coronaviruses hcovs including severe acute respiratory syndrome coronavirus sars cov middle east respiratory syndrome coronavirus mers cov and novel coronavirus ncov lead global epidemics with high morbidity and mortality however there are currently no effective drugs targeting ncov drug repurposing represented as an effective drug discovery strategy from existing drugs could shorten the time and reduce the cost compared to de novo drug discovery in this study we present an integrative antiviral drug repurposing methodology implementing a systems pharmacology based network medicine platform quantifying the interplay between the hcov host interactome and drug targets in the human protein protein interaction network phylogenetic analyses of hcov whole genomes reveal that ncov has the highest nucleotide sequence identity with sars cov among the six other known pathogenic hcovs specifically the envelope and nucleocapsid proteins of ncov are two evolutionarily conserved regions having the sequence identities of and respectively compared to sars cov using network proximity analyses of drug targets and known hcov host interactions in the human protein protein interactome we computationally identified putative repurposable drugs for the potential prevention and treatment of hcovs in addition we prioritized potential anti hcov repurposable drugs including melatonin mercaptopurine and sirolimus that were further validated by enrichment analyses of drug gene signatures and hcov induced transcriptomics data in human cell lines finally we showcased three potential drug combinations including sirolimus plus dactinomycin mercaptopurine plus melatonin and toremifene plus emodin captured by the complementary exposure pattern the targets of the drugs both hit the hcov host subnetwork but target separate neighborhoods in the human protein protein interactome network in summary this study offers powerful network based methodologies for rapid identification of candidate repurposable drugs and potential drug combinations toward future clinical trials for hcovs

ID: 4yuw7jo3,
Text: network based drug repurposing for novel coronavirus ncov sars cov human coronaviruses hcovs including severe acute respiratory syndrome coronavirus sars cov and novel coronavirus ncov also known as sars cov lead global epidemics with high morbidity and mortality however there are currently no effective drugs targeting ncov sars cov drug repurposing representing as an effective drug discovery strategy from existing drugs could shorten the time and reduce the cost compared to de novo drug discovery in this study we present an integrative antiviral drug repurposing methodology implementing a systems pharmacology based network medicine platform quantifying the interplay between the hcov host interactome and drug targets in the human protein protein interaction network phylogenetic analyses of hcov whole genomes reveal that ncov sars cov shares the highest nucleotide sequence identity with sars cov specifically the envelope and nucleocapsid proteins of ncov sars cov are two evolutionarily conserved regions having the sequence identities of and respectively compared to sars cov using network proximity analyses of drug targets and hcov host interactions in the human interactome we prioritize potential anti hcov repurposable drugs e g melatonin mercaptopurine and sirolimus that are further validated by enrichment analyses of drug gene signatures and hcov induced transcriptomics data in human cell lines we further identify three potential drug combinations e g sirolimus plus dactinomycin mercaptopurine plus melatonin and toremifene plus emodin captured by the complementary exposure pattern the targets of the drugs both hit the hcov host subnetwork but target separate neighborhoods in the human interactome network in summary this study offers powerful network based methodologies for rapid identification of candidate repurposable drugs and potential drug combinations targeting ncov sars cov

ID: qnccsstb,
Text: host transcriptome guided drug repurposing for covid treatment a meta analysis based approach background coronavirus disease covid caused by severe acute respiratory syndrome coronavirus sars cov has been declared a pandemic by the world health organization and the identification of effective therapeutic strategy is a need of the hour to combat sars cov infection in this scenario the drug repurposing approach is widely used for the rapid identification of potential drugs against sars cov considering viral and host factors methods we adopted a host transcriptome based drug repurposing strategy utilizing the publicly available high throughput gene expression data on sars cov and other respiratory infection viruses based on the consistency in expression status of host factors in different cell types and previous evidence reported in the literature pro viral factors of sars cov identified and subject to drug repurposing analysis based on drugbank and connectivity map cmap using the web tool clue results the upregulated pro viral factors such as tymp ptgs c s cfb ifi xaf cxcl and cxcl were identified in early infection models of sars cov by further analysis of the drug perturbed expression profiles in the connectivity map drugs that can reverse the expression of pro viral factors were identified and importantly twelve of them reported to have anti viral activity the direct inhibition of the ptgs gene product can be considered as another therapeutic strategy for sars cov infection and could suggest six approved ptgs inhibitor drugs for the treatment of covid the computational study could propose candidate repurposable drugs against covid and further experimental studies are required for validation

ID: xui8cfzv,
Text: repurposing cefuroxime for treatment of covid a scoping review of in silico studies severe acute respiratory syndrome coronavirus sars cov the causative agent of coronavirus disease covid is a novel human coronavirus that is responsible for about deaths worldwide to date there is no confirmed treatment or vaccine prevention strategy against covid due to the urgent need for effective treatment drug repurposing is regarded as the immediate option potential drugs can often be identified via in silico drug screening experiments consequently there has been an explosion of in silico experiments to find drug candidates or investigate anecdotal claims one drug with several anecdotal accounts of benefit is cefuroxime the aim of this study was to identify and summarize in silico evidence for possible activity of cefuroxime against sars cov to this end we performed a scoping review of literature of in silico drug repurposing experiments for sars cov using prisma scr we searched medline embase scopus web of knowledge and google scholar for original studies published between st feb and th may that screened drug libraries and identified cefuroxime as a top ranked potential inhibitor drug against sars cov proteins six studies were identified these studies reported cefuroxime as a potential inhibitor of key sars cov proteins main protease rna dependent rna polymerase and ace spike complex we provided a summary of the methodology and findings of the identified studies our scoping review identified significant in silico evidence that cefuroxime may be a potential multi target inhibitor of sars cov further in vitro and in vivo studies are required to evaluate the potential of cefuroxime for covid communicated by ramaswamy h sarma

ID: kq3qnhap,
Text: mass drug administration and worms experience in africa envisage repurposing ivermectin for sars cov mass drug administration and worms experience in africa envisage repurposing ivermectin for sars cov

ID: ip4wpdib,
Text: overcoming cancer therapeutic bottleneck by drug repurposing ever present hurdles for the discovery of new drugs for cancer therapy have necessitated the development of the alternative strategy of drug repurposing the development of old drugs for new therapeutic purposes this strategy with a cost effective way offers a rare opportunity for the treatment of human neoplastic disease facilitating rapid clinical translation with an increased understanding of the hallmarks of cancer and the development of various data driven approaches drug repurposing further promotes the holistic productivity of drug discovery and reasonably focuses on target defined antineoplastic compounds the treasure trove of non oncology drugs should not be ignored since they could target not only known but also hitherto unknown vulnerabilities of cancer indeed different from targeted drugs these old generic drugs usually used in a multi target strategy may bring benefit to patients in this review aiming to demonstrate the full potential of drug repurposing we present various promising repurposed non oncology drugs for clinical cancer management and classify these candidates into their proposed administration for either mono or drug combination therapy we also summarize approaches used for drug repurposing and discuss the main barriers to its uptake

ID: d9v8qo7v,
Text: drug repurposing a better approach for infectious disease drug discovery the advent of publically available databases containing system wide phenotypic data of the host response to both drugs and pathogens in conjunction with bioinformatics and computational methods now allows for in silico predictions of fda approved drugs as treatments against infection diseases this systems biology approach captures the complexity of both the pathogen and drug host response in the form of expression patterns or molecular interaction networks without having to understand the underlying mechanisms of action these drug repurposing techniques have been successful in identifying new drug candidates for several types of cancers and were recently use to identify potential therapeutics against influenza the newly discovered middle eastern respiratory syndrome coronavirus and several parasitic diseases these new approaches have the potential to significantly reduce both the time and cost for infectious diseases drug discovery

ID: aqge7xuu,
Text: repurposing cefuroxime for treatment of covid a scoping review of in silico studies severe acute respiratory syndrome coronavirus sars cov the causative agent of coronavirus disease covid is a novel human coronavirus that is responsible for about deaths worldwide to date there is no confirmed treatment or vaccine prevention strategy against covid due to the urgent need for effective treatment drug repurposing is regarded as the immediate option potential drugs can often be identified via in silico drug screening experiments consequently there has been an explosion of in silico experiments to find drug candidates or investigate anecdotal claims one drug with several anecdotal accounts of benefit is cefuroxime the aim of this study was to identify and summarize in silico evidence for possible activity of cefuroxime against sars cov to this end we performed a scoping review of literature of in silico drug repurposing experiments for sars cov using prisma scr we searched medline embase scopus web of knowledge and google scholar for original studies published between st feb and th may that screened drug libraries and identified cefuroxime as a top ranked potential inhibitor drug against sars cov proteins six studies were identified these studies reported cefuroxime as a potential inhibitor of key sars cov proteins main protease rna dependent rna polymerase and ace spike complex we provided a summary of the methodology and findings of the identified studies our scoping review identified significant in silico evidence that cefuroxime may be a potential multi target inhibitor of sars cov further in vitro and in vivo studies are required to evaluate the potential of cefuroxime for covid communicated by ramaswamy h sarma

ID: fdrrbr6a,
Text: repurposing of miglustat to inhibit the coronavirus severe acquired respiratory syndrome sars cov repurposing clinically available drugs to treat the new coronavirus disease covid is an urgent need in these early stages of the sars cov pandemic when very few treatment options are available the iminosugar miglustat is a well characterized drug for the treatment of rare genetic lysosome storage diseases such as gaucher and niemann pick type c and has also been described to be active against a variety of enveloped viruses the activity of miglustat is here demonstrated for sars cov at concentrations achievable in the plasma by current clinical regimens without cytotoxicity the drug acts at the post entry level and leads to a marked decrease of viral proteins and release of infectious virus the mechanism resides in the inhibitory activity towards Î± glucosidases that are involved in early stages of glycoprotein n linked oligosaccharide processing in the endoplasmic reticulum leading to a marked decrease of the viral spike protein the wealth of available data on the clinical use of miglustat for the treatment of lysosomal storage disorders and the antiviral properties against sars cov make it an ideal candidate for drug repurposing

ID: 9idkf0i9,
Text: an update on therapeutic repurposing strategies for covid the severe acute respiratory syndrome coronavirus well known as covid has become the current health distress to the entire world in the pandemic scenario the research on the rapid development of new drug molecules is highly risky and tedious process the current covid emergency demands an urgent development of possible strategies to protect people at high risk of infection and hence the drug repurposing became an emerging approach to fight covid this review summarizes an update on various therapeutic strategies with special attention on repurposing of drugs to fight against sars cov worldwide the investigation of existing drugs for new therapeutic purposes is one line of scientific research followed to develop safe and effective covid treatments broad spectrum antiviral agents bsaas that have been believed to be safe through testing on early phase clinical trials have been hyped as good drug repurposing candidates broad spectrum antiviral drugs such as ribavirin umifenovir were advised for covid treatment some antibiotics may be repurposed as covid treatments such as teicoplanin oritavancin dalbavancin monensin and azithromycin ivermectin an antiparasitic is recently repurposed hydroxychloroquine and chloroquine having immunomodulating effect on humans have been shown to have antiviral activity at starting and post entry stages of the sars cov infection there is a need for global health emergency to call for a courageous global response at the political and governmental levels therefore the regulatory agencies must act swiftly to lessen any financial obstacles involving private companies and update guidelines for drug licenses by repurposing if necessary

ID: 4h73lukj,
Text: drug repurposing to fight colistin and carbapenem resistant bacteria the emergence of new resistance mechanisms the failure of classical antibiotics in clinic the decrease in the development of antibiotics in the industry are all challenges that lead us to consider new strategies for the treatment of infectious diseases indeed in recent years controversy has intensified over strains resistant to carbapenem and or colistin various therapeutic solutions are used to overcome administration of last line antibiotics in this context drug repurposing which consists of using a non antibiotic compound to treat multi drug resistant bacteria mdr is encouraged in this review we first report what may have led to drug repurposing main definitions advantages and drawbacks are summarized three major methods are described phenotypic computational and serendipity in a second time we will focus on the current knowledge in drug repurposing for carbapenem and colistin resistant bacteria with different studies describing repurposed compounds tested on gram negative bacteria furthermore we show that drug combination therapies can increase successful by drug repurposing strategy in conclusion we discuss the pharmaceutical industries that have little interest in reprofiling drugs due to lack of profits we also consider what a clinician might think of the indications of these uncommon biologists to treat mdr bacterial infections and avoid therapeutic impasses

ID: r5p5helx,
Text: drug repurposing for breast cancer therapy old weapon for new battle abstract despite tremendous resources being invested in prevention and treatment breast cancer remains a leading cause of cancer deaths in women globally the available treatment modalities are very costly and produces severe side effects drug repurposing that relate to new uses for old drugs has emerged as a novel approach for drug development repositioning of old clinically approved off patent non cancer drugs with known targets into newer indication is like using old weapons for new battle the advances in genomics proteomics and information computational biology has facilitated the process of drug repurposing repositioning approach not only fastens the process of drug development but also offers more effective cheaper safer drugs with lesser known side effects during the last decade drugs such as alkylating agents anthracyclins antimetabolite cdk inhibitor aromatase inhibitor mtor inhibitor and mitotic inhibitors has been repositioned for breast cancer treatment the repositioned drugs have been successfully used for the treatment of most aggressive triple negative breast cancer the literature review suggest that serendipity plays a major role in the drug development this article describes the comprehensive overview of the current scenario of drug repurposing for the breast cancer treatment the strategies as well as several examples of repurposed drugs are provided the challenges associated with drug repurposing are discussed

ID: a1p1nopl,
Text: new sources of drugs for hematologic malignancies advancing novel therapeutic agents for the treatment of malignancy into the marketplace is an increasingly costly and lengthy process as such new strategies for drug discovery are needed drug repurposing represents an opportunity to rapidly advance new therapeutic strategies into clinical trials at a relatively low cost known on patent or off patent drugs with unrecognized anticancer activity can be rapidly advanced into clinical testing for this new indication by leveraging their known pharmacology pharmacokinetics and toxicology using this approach academic groups can participate in the drug discovery field and smaller biotechnology companies can de risk early stage drug discovery projects here several scientific approaches used to identify drug repurposing opportunities are highlighted with a focus on hematologic malignancies in addition a discussion of the regulatory issues that are unique to drug repurposing and how they impact developing old drugs for new indications is included finally the mechanisms to enhance drug repurposing through increased collaborations between academia industry and nonprofit charitable organizations are discussed

ID: 738881m2,
Text: deeppurpose a deep learning library for drug target interaction prediction and applications to repurposing and screening accurate prediction of drug target interactions dti enables drug discovery tasks including virtual screening and drug repurposing which can shorten the time to identify promising drug candidates and provide cures to patients recently there is a growing number of research that developed deep learning dl models for dti despite their superior performance these research models are difficult to use in real drug discovery practice due to the complexity of deploying the research code as well as the restricted data formatting model capacity and evaluation setting we present deeppurpose a comprehensive and easy to use software toolkit for dl based drug target interaction dti prediction with applications to drug screening and repurposing the unique feature of deeppurpose is that it enables non computational drug development scientists to identify drug candidates based on five pre trained dl models with only a few lines of codes further computer scientists can use deeppurpose to train customized dti prediction models with drug and target encodings and novel dl architectures to tackle method development challenges deeppurpose also supports various data split settings and preloads five benchmarking datasets we demonstrated that deeppurpose allows users to obtain state of the art prediction performance on several benchmark datasets we also presented several case studies including a study on drug repurposing for covid where promising drug candidates currently investigated in clinical trials are ranked high in deeppurpose predictions

ID: 1762jnw8,
Text: drug repurposing for antimicrobial discovery antimicrobial resistance continues to be a public threat on a global scale the ongoing need to develop new antimicrobial drugs that are effective against multi drug resistant pathogens has spurred the research community to invest in various drug discovery strategies one of which is drug repurposing the process of finding new uses for existing drugs while still nascent in the antimicrobial field the approach is gaining traction in both the public and private sector while the approach has particular promise in fast tracking compounds into clinical studies it nevertheless has substantial obstacles to success this review covers the art of repurposing existing drugs for antimicrobial purposes we discuss enabling screening platforms for antimicrobial discovery and present encouraging findings of novel antimicrobial therapeutic strategies also covered are general advantages of repurposing over de novo drug development and challenges of the strategy including scientific intellectual property and regulatory issues

ID: 7cjm2yp0,
Text: exploring the sars cov virus host drug interactome for drug repurposing coronavirus disease covid is an infectious disease caused by the sars cov virus it was first identified in wuhan china and has since spread causing a global pandemic various studies have been performed to understand the molecular mechanisms of viral infection for predicting drug repurposing candidates however such information is spread across many publications and it is very time consuming to access integrate explore and exploit we developed covex the first interactive online platform for sars cov and sars cov host interactome exploration and drug target identification covex integrates experimentally validated virus human protein interactions human protein protein interactions and drug target interactions the web interface allows user friendly visual exploration of the virus host interactome and implements systems medicine algorithms for network based prediction of drugs thus covex is an important resource not only to understand the molecular mechanisms involved in sars cov and sars cov pathogenicity but also in clinical research for the identification and prioritization of candidate therapeutics we apply covex to investigate recent hypotheses on a systems biology level and to systematically explore the molecular mechanisms driving the virus life cycle furthermore we extract and discuss drug repurposing candidates involved in these mechanisms covex renders covid drug research systems medicine ready by giving the scientific community direct access to network medicine algorithms integrating virus host drug interactions it is available at https exbio wzw tum de covex

ID: 7jhjlxtf,
Text: drug repurposing for viral infectious diseases how far are we despite the recent advances in controlling some viral pathogens most viral infections still lack specific treatment indeed the need for effective therapeutic strategies to combat old emergent and re emergent viruses is not paralleled by the approval of new antivirals in the past years drug repurposing combined with innovative approaches for drug validation and with appropriate animal models significantly contributed to the identification of new antiviral molecules and targets for therapeutic intervention in this review we describe the main strategies of drug repurposing in antiviral discovery discuss the most promising candidates that could be repurposed to treat viral infections and analyze the possible caveats of this trendy strategy of drug discovery

ID: njeyvdd2,
Text: a medicinal chemistry perspective of drug repositioning recent advances and challenges in drug discovery drug repurposing is a strategy consisting of finding new indications for already known marketed drugs used in various clinical settings or highly characterized compounds despite they can be failed drugs recently it emerges as an alternative approach for the rapid identification and development of new pharmaceuticals for various rare and complex diseases for which lack the effective drug treatments the success rate of drugs repurposing approach accounts for approximately of new fda approved drugs and vaccines in recent years this review focuses on the status of drugs repurposing approach for various diseases including skin diseases infective inflammatory cancer and neurodegenerative diseases efforts have been made to provide structural features and mode of actions of drugs

ID: ruvz3f1c,
Text: genetically informed precision drug repurposing for lung function and implications for respiratory infection impaired lung function is associated with significant morbidity and mortality restrictive and obstructive lung disorders are a large contributor to decreased lung function as well as the acute impact of infection measures of pulmonary function are heritable and thus we sought to utilise genomics to propose novel drug repurposing candidates which could improve respiratory outcomes lung function measures were found to be genetically correlated with metabolic and hormone traits which could be pharmacologically modulated with a causal effect of increased fasting glucose on diminished lung function supported by latent causal variable models and mendelian randomisation we developed polygenic scores for lung function specifically within pathways with known drug targets to prioritise individuals who may benefit from particular drug repurposing opportunities accompanied by transcriptome wide association studies to identify drug gene interactions with potential lung function increasing modes of action these drug repurposing candidates were further considered relative to the host viral interactome of three viruses with associated respiratory pathology sars cov influenza and human adenovirus we uncovered an enrichment amongst glycaemic pathways of human proteins which putatively interact with virally expressed sars cov proteins suggesting that antihyperglycaemic agents may have a positive effect both on lung function and sars cov progression

ID: j5nmifhj,
Text: pharmacodynamics and systems pharmacology approaches to repurposing drugs in the wake of global health burden abstract there are emergent needs for cost effective treatment worldwide for which repurposing to develop a drug with existing marketing approval of disease s for new disease s is a valid option although strategic mining of electronic health records has produced real world evidences to inform drug repurposing using omics data drug and disease knowledge base of protein interactions and database of transcription factors have been explored structured integration of all the existing data under the framework of drug repurposing will facilitate decision making the ability to foresee the need to integrate new data types produced by emergent technologies and to enable data connectivity in the context of human biology and targeted diseases as well as to use the existing crucial quality data of all approved drugs will catapult the number of drugs being successfully repurposed however translational pharmacodynamics databases for modeling information across human biology in the context of host factors are lacking and are critically needed for drug repurposing to improve global public health especially for the efforts to combat neglected tropic diseases as well as emergent infectious diseases such as zika or ebola virus
